Short Interest in Sensus Healthcare, Inc. (NASDAQ:SRTS) Declines By 18.3%

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the target of a significant decrease in short interest during the month of March. As of March 13th, there was short interest totaling 394,950 shares, a decrease of 18.3% from the February 26th total of 483,655 shares. Currently, 2.6% of the shares of the company are short sold. Based on an average daily trading volume, of 102,973 shares, the short-interest ratio is currently 3.8 days.

Institutional Investors Weigh In On Sensus Healthcare

Large investors have recently modified their holdings of the stock. Pacific Ridge Capital Partners LLC lifted its position in shares of Sensus Healthcare by 21.8% during the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock worth $2,781,000 after buying an additional 125,245 shares during the period. Divisadero Street Capital Management LP grew its position in Sensus Healthcare by 39.5% in the third quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock valued at $1,422,000 after acquiring an additional 128,224 shares during the period. Geode Capital Management LLC raised its stake in Sensus Healthcare by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock worth $630,000 after acquiring an additional 5,316 shares in the last quarter. Sachetta LLC raised its stake in Sensus Healthcare by 6.8% during the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock worth $591,000 after acquiring an additional 9,500 shares in the last quarter. Finally, Greenline Wealth Management LLC bought a new position in shares of Sensus Healthcare during the fourth quarter valued at $513,000. 25.30% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Wall Street Zen downgraded Sensus Healthcare from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. Maxim Group cut their price target on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Alliance Global Partners assumed coverage on Sensus Healthcare in a research report on Friday, March 6th. They issued a “buy” rating and a $7.50 price objective for the company. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a report on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.88.

Sensus Healthcare Stock Performance

Shares of NASDAQ:SRTS traded up $0.17 during midday trading on Tuesday, reaching $4.04. 8,842 shares of the company’s stock were exchanged, compared to its average volume of 92,900. The company’s 50 day simple moving average is $4.38 and its two-hundred day simple moving average is $3.98. Sensus Healthcare has a 12 month low of $3.03 and a 12 month high of $5.92. The firm has a market capitalization of $66.50 million, a PE ratio of -8.60 and a beta of 1.22.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, February 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.10). Sensus Healthcare had a negative net margin of 28.09% and a negative return on equity of 15.11%. The business had revenue of $4.94 million during the quarter, compared to the consensus estimate of $8.35 million. On average, research analysts anticipate that Sensus Healthcare will post 0.32 earnings per share for the current year.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.